SPYRE THERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
SPYRE THERAPEUTICS, INC. (SYRE) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-02-19
- SPYRE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-12-31 was $0.00.
- SPYRE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-09-30 was $0.00.
- SPYRE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- SPYRE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- SPYRE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $0.00.
- SPYRE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- SPYRE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $220.00K, a 44.58% decline from fiscal 2022.
- SPYRE THERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $397.00K, a 6.59% decline from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-19 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 |
| 2024-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $0.00 derived: sum of 2 quarters · filed 2024-11-18 | $0.00 10-Q/A · filed 2024-11-18 | $0.00 derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $0.00 10-Q/A · filed 2024-11-18 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $0.00 10-Q/A · filed 2024-11-18 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $56.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $56.00K derived: sum of 3 quarters · filed 2026-02-19 | $220.00K 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $56.00K derived: sum of 2 quarters · filed 2024-11-18 | $220.00K 10-Q/A · filed 2024-11-18 | $325.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $56.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $220.00K 10-Q/A · filed 2024-11-18 | $325.00K derived: sum of 3 quarters · filed 2025-02-27 | $426.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $164.00K 10-Q/A · filed 2024-11-18 | $269.00K derived: sum of 2 quarters · filed 2025-02-27 | $370.00K derived: sum of 3 quarters · filed 2025-02-27 | $467.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $206.00K derived: sum of 2 quarters · filed 2025-02-27 | $303.00K derived: sum of 3 quarters · filed 2025-02-27 | $397.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $101.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $198.00K derived: sum of 2 quarters · filed 2023-11-09 | $292.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $97.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $191.00K 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $94.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $425.00K 10-K/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |